Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Common Equity (2016 - 2026)

Standard Biotools has reported Common Equity over the past 16 years, most recently at $424.3 million for Q4 2025.

  • Quarterly Common Equity fell 10.05% to $424.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $424.3 million through Dec 2025, down 10.05% year-over-year, with the annual reading at $424.3 million for FY2025, 10.05% down from the prior year.
  • Common Equity was $424.3 million for Q4 2025 at Standard Biotools, up from $399.7 million in the prior quarter.
  • Over five years, Common Equity peaked at $577.3 million in Q1 2024 and troughed at -$148.1 million in Q4 2023.
  • The 5-year median for Common Equity is $104.4 million (2021), against an average of $176.4 million.
  • Year-over-year, Common Equity crashed 539.35% in 2023 and then soared 694.23% in 2024.
  • A 5-year view of Common Equity shows it stood at $94.6 million in 2021, then tumbled by 186.12% to -$81.5 million in 2022, then plummeted by 81.73% to -$148.1 million in 2023, then surged by 418.62% to $471.7 million in 2024, then dropped by 10.05% to $424.3 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Common Equity are $424.3 million (Q4 2025), $399.7 million (Q3 2025), and $424.5 million (Q2 2025).